✦ LIBER ✦

Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma

✍ Scribed by Jae Yong Cho; Yong Han Paik; Yoon Soo Chang; Se Joon Lee; Dong-Ki Lee; Si Young Song; Jae Bock Chung; Mi-Suk Park; Jeong-Sik Yu; Dong-Sup Yoon

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 107 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized multicenter Phase II trial of

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

✍ Emilio Bajetta; Maria Di Bartolomeo; Luigi Mariani; Antonio Cassata; Salvatore A 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

## Abstract ## BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first‐line treatment in metastatic colorectal carcinoma (CRC). ## METHODS A total of 140 patients received capecitabine at a dose of 1

The combination of gemcitabine and carbo

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma : A Phase II study of the Hellenic Cooperative Oncology Group

✍ Aristotle Bamias; Lia A. Moulopoulos; Aggelos Koutras; Gerassimos Aravantinos; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract ## BACKGROUND The toxicity of platinum‐based combinations represents a common problem for patients with advanced urothelial carcinoma. The authors previously reported encouraging efficacy for the combination of carboplatin and gemcitabine in patients considered to be unfit for cisplati

Phase II study of paclitaxel and epirubi

Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma

✍ Giovanni L. Ceresoli; Stefania Dell'Oro; Paolo Passoni; Eugenio Villa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

A multicenter, randomized, Phase II stud

A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma

✍ Filippo De Marinis; Fabrizio Nelli; Marco Lombardo; Francesco Ferraú; Santi Barb 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and toxicity of combined cisplatin, etoposide, and gemcitabine (PEG) and combined cisplatin plus gemcitabine (PG) in previously untreated patients with extensive‐stage and poor‐prognosis limited‐stage small‐cell lun

Weekly docetaxel with either gemcitabine

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma : Phase II trials of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Howard A. Burris III; Frederic T. Billings III; James E. Bra 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

Weekly combination chemotherapy with doc

Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma : A Minnie Pearl Cancer Research Network Phase II Trial

✍ John D. Hainsworth; Donna Carrell; Ronald L. Drengler; Carroll Scroggin Jr.; F. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

## Abstract ## BACKGROUND The goal of the current study was to evaluate the feasibility, toxicity, and efficacy of a novel combination of weekly docetaxel and gemcitabine for elderly patients and patients with poor performance status who had advanced‐stage small cell lung carcinoma (SCLC). ## MET